Source: Kapitales ResearchHighlights:

• China supply disruption trimmed infant formula sales, but recovery is already underway.
• FY26 earnings are still expected to meet or exceed previous guidance.
• Strong cash conversion and broader product growth strengthen the long-term outlook.

Market SnapshotThe a2 Milk Company Limited (ASX: A2M) trading around AU$7.980 after releasing a supply chain and FY26 trading update, with the stock gaining approximately 3.50% during the session.China Supply Challenges Tested FY26 PerformanceThe a2 Milk Company has reassured investors that its FY26 financial performance is expected to remain in line with, or marginally ahead of, its previous guidance despite significant supply chain disruptions affecting its China-labelled infant milk formula business during the final quarter of the financial year. The disruption stemmed from a combination of stronger-than-anticipated demand, freight constraints, production delays at manufacturing partner Synlait, extended product release timelines, and tighter customs clearance and testing requirements in China. These factors reduced product availability across distributors and retailers, prompting many customers to temporarily switch to competing brands. Broader Portfolio Helps Offset WeaknessAlthough China-labelled infant formula sales declined by approximately 14% compared with FY25, the company's wider portfolio delivered encouraging growth. English-labelled infant formula, liquid milk products and other nutritional offerings all recorded strong year-on-year improvements, helping cushion the impact of weaker China-labelled sales. Based on preliminary unaudited results, the company expects FY26 revenue of approximately AU$1.97 billion, representing growth of more than 12% over FY25. EBITDA margin is forecast to finish at the upper end of the previously guided 14.0% to 14.5% range, while reported net profit is expected to be slightly higher than the previous year. Cash conversion is also projected to improve significantly to around 70%, well above the earlier expectation of 50%. Recovery Efforts Already UnderwayManagement said the supply constraints have now been largely resolved, with product availability returning to targeted inventory levels across both China-labelled and English-labelled ranges. The company has shifted its focus towards rebuilding market share by encouraging former customers to return while accelerating new customer acquisition through retail and distribution partnerships. These initiatives are expected to support momentum as normal product flows resume across key sales channels.OutlookThe latest update suggests the disruption was operational rather than structural, providing reassurance that underlying consumer demand for the a2 Milk brand remains resilient. With inventory levels normalising, stronger cash generation, and diversified product categories continuing to perform well, the company appears well positioned to enter FY27 from a stronger operational footing. Investors will closely monitor the release of the company's audited FY26 results and FY27 outlook on 17 August 2026, which should provide greater clarity on the pace of customer recovery and future earnings growth. Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au